Mineralocorticoid receptor antagonist use in renal dialysis: will evidence from prospective randomized trials confirm the results from ‘real‐world’ evidence?-Reference-Cited by-同舟云学术

Mineralocorticoid receptor antagonist use in renal dialysis: will evidence from prospective randomized trials confirm the results from ‘real‐world’ evidence?

Published:2023-03 Issue:3 Volume:25 Page:361-363
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European J of Heart Fail

Author:

Rossignol Patrick¹²,Pitt Bertram³

Affiliation:

1. Université de Lorraine, Centre d'Investigations Cliniques‐ Plurithématique 14‐33, Inserm U1116, CHRU Nancy, and F‐CRIN INI‐CRCT (Cardiovascular and Renal Clinical Trialists) Nancy France

2. Medicine and Nephrology‐Dialysis Departments Princess Grace Hospital, and Monaco Private Hemodialysis Centre Monaco Monaco

3. University of Michigan School of Medicine Ann Arbor MI USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2804

Reference16 articles.

1. Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints

2. The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward

3. Cardiorenal Syndrome Revisited

4. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease

5. Heart failure drug treatment

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA);Clinical Kidney Journal;2023-06-24